Micro Interventional Devices Inc. (MID) recently announced the second successful implantation of its MIA (Minimally Invasive Annuloplasty) technology. The patient was enrolled in the first arm of the STTAR (Study of Transcatheter Tricuspid Annular Repair) clinical trial studying the safety and efficacy of MID's MIA device designed to eliminate or greatly reduce tricuspid regurgitation.

CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's ongoing clinical trial of its proprietary Cobra PzF NanoCoated Coronary Stent (NCS) with 14-day dual antiplatelet therapy (DAPT) in complex patients, such as those who are at high bleeding risk. The COBRA REDUCE trial is the world's first and only randomized control trial to assess 14-day DAPT after percutaneous coronary intervention (PCI), according to the company.

CorInnova Inc. announced it has received notice of allowance of a seminal patent to protect its intellectual property associated with the world’s first minimally invasively-delivered soft robotic heart device to support heart function. The company also announced that it has become a resident at Johnson & Johnson Innovation, JLABS at the Texas Medical Center (JLABS @ TMC). This residency follows a $6.1 million funding from the Wellcome Trust, details of which have not been disclosed.

October 26, 2017 — The National Institutes of Health has awarded Detroit cardiologist Adam Greenbaum, M.D., for his ...

Medical professionals representing hospital systems from across the United States are expected to attend the first National Cardiogenic Shock Initiative (NCSI) meeting Oct. 29 in Denver. The gathering will help kick off Transcatheter Cardiovascular Therapeutics (TCT) 2017, an annual educational meeting specializing in interventional cardiovascular medicine.

Amaranth Medical will provide an update at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting, Oct. 29-Nov. 2 in Denver, on the company’s full line of sirolimus-eluting bioresorbable scaffold (BRS) products during a satellite breakfast meeting and in an oral presentation on Oct. 31.

Philips recently announced the key findings of its research focused on the patient experience in diagnostic imaging procedures. Philips’ Patient Experience in Imaging Study surveyed 603 patients in the United States and Germany about their satisfaction, expectations, preferences and unmet needs with diagnostic imaging procedures in the past year. Patients identified trust in the referring doctor, communication, comfort, safety and getting the image right the first time as key priorities. The research provides insight into how patients perceive imaging procedures, what they value during the process, and what healthcare professionals can do to create a more patient-centered imaging experience.